Commenting on the action in Monster Beverage this afternoon, Goldman Sachs analyst Judy Hong called the FDA's response to the energy drink safety issue "generally benign." Hong believes this should be encouraging for Monster. The analyst believes the most likely outcome related to Durbin's energy drink review will be strong